CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Patient-tailored antithrombotic therapy following percutaneous coronary intervention

Review Article2020 Jul 1;9(7):E2064.

JOURNAL:J Clin Med . Article Link

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective

G Tersalvi, L Biasco, GM Cioffi et al. Keywords: P2Y12 inhibition; acute coronary syndrome; bleeding; clopidogrel; dual antiplatelet therapy; high bleeding risk; prasugrel; tailored therapy; ticagrelor

Full Text PDF